A Phase 2 Multicenter, Randomized, Doubleblind, Placebo–Controlled, Dose Range Finding Study to Evaluate the Efficacy and Safety of Intramuscular Injection of Human Placenta-Derived Cells (pda-002) in Subjects who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease. Protocol Number: cct-pda-002-dfu-002.
Investigator: Arash Bornak
Institutional Protocol #: 20140600
National Clinical Trials Identifier: NCT02264288
Therapeutic Area: Other
Phase: Phase II
Enrolling Since: 2/19/2016